Publication:
Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.

Simple item page
dc.contributor.authorGonzález-Bertolín, Isabel
dc.contributor.authorAlcolea, Sonia
dc.contributor.authorAlonso, Patricia
dc.contributor.authorArroyas, María
dc.contributor.authorFernández Castiella, Isabel
dc.contributor.authorEchavarren, Iciar
dc.contributor.authorIglesias-Caballero, Maria
dc.contributor.authorCasas Flecha, Inmaculada
dc.contributor.authorGarcía-García, María Luz
dc.contributor.authorCalvo, Cristina
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Comisión Europea. Horizonte Europa
dc.contributor.funderMerck, Sharp & Dohme
dc.date.accessioned2026-09-08T17:50:56Z
dc.date.available2026-09-08T17:50:56Z
dc.date.issued2025-10-01
dc.description.abstractNirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab's safety as a preventive strategy.
dc.description.peerreviewedSí
dc.description.sponsorshipThis study has been funded by the Instituto de Salud Carlos III (ISCIII) through the projects PI24/00212, PI21CIII/00019, and PI21/00377, and co-funded by the European Union. Also, funding was received from EU4H2022-Grant Agreement-101113109 and by CLARITY-Horizon Europe Programme-GA-101137201 and from Merck Sharp Dohme MISP: IISP 102677.
dc.format.number10
dc.format.page1009-1011
dc.format.volume44
dc.identifier.citationGonzález-Bertolín, I., Alcolea, S., Alonso, P., Arroyas, M., Fernández Castiella, I., Echavarren, I., Iglesias-Caballero, M., Casas, I., García-García, M. L., & Calvo, C. (2025). Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season. Pediatric Infectious Disease Journal, 44(10), 1009–1011. https://doi.org/10.1097/INF.0000000000004920.
dc.identifier.doi10.1097/INF.0000000000004920
dc.identifier.journalThe Pediatric Infectious Disease Journal
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27697
dc.language.isoeng
dc.publisherWolters Kluwer
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI24%2F00212/ES/IMPACTO A MEDIO PLAZO DE LA PREVENCIÓN CONTRA EL VIRUS RESPIRATORIO SINCITIAL/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/AES - Intramural/PI21CIII%2F00019//INFECCION RESPIRATORIA AGUDA EN NIÑOS TRAS 2 AÑOS DE PANDEMIA DE SARS-CoV-2: VIRUS Y RESPUESTA INMUNE/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PI21%2F00377/ES/IMPACTO DE LA PANDEMIA COVID-19 EN LAS INFECCIONES RESPIRATORIAS VIRALES, RESPUSTA INMUNE Y MICROBIOTA EN EL PRIMER AÑO DE VIDA, INCLUYENDO RECIEN NACIDOS PREMATUROS/
dc.relation.projectIDinfo:eu-repo/grantAgreement/EU/EU4H-2022/101113109///
dc.relation.projectIDinfo:eu-repo/grantAgreement/EU/CLARITY-Horizon Europe Programme-GA/101137201///
dc.relation.projectIDinfo:eu-repo/grantAgreement/Merck Sharp Dohme MISP//IISP 102677///
dc.relation.publisherversionhttps://doi.org/10.1097/INF.0000000000004920
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAntibody-dependent enhancement
dc.subjectImmunization
dc.subjectNirsevimab
dc.subjectRespiratory syncytial virus
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshAntiviral Agents
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshMale
dc.subject.meshRespiratory Syncytial Virus Infections
dc.subject.meshRespiratory Syncytial Virus, Human
dc.subject.meshSeasons
dc.subject.meshTreatment Outcome
dc.titleSecond-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationf055c52d-7163-4b68-8701-12a3b6533144
relation.isAuthorOfPublicatione2df6e55-f1d3-423b-a72f-fd9a69cf5915
relation.isAuthorOfPublication.latestForDiscoveryf055c52d-7163-4b68-8701-12a3b6533144
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication00cde69c-0ce1-44c4-ab2f-221edcf8dcca
relation.isFunderOfPublication0af19d44-b1aa-474e-9aaa-28c40dc292b3
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublicationb2ca5f78-d34e-49de-aa94-ad7eb84e67f6
relation.isPublisherOfPublication.latestForDiscoveryb2ca5f78-d34e-49de-aa94-ad7eb84e67f6

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
SecondSeasonImpactNirsevimab_2025.pdf
Size:
379.53 KB
Format:
Adobe Portable Document Format
Download

Collections

Centro Nacional de Microbiología (CNM)